window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : May 1, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Research & Development

  • Artificial Intelligence,Biotech,Chronic diseases,Partnerships & Funding,Pharmaceuticals and therapeutics,Research & Development,Single Cell analysis,Technology and platforms

    Immunai signs $85 million AstraZeneca deal to advance inflammatory bowel disease target

    Immunai has signed an agreement worth up to $85 million [...]

    October 16, 2025
  • Biotech,Cell & Gene Therapy,Partnerships & Funding,Research & Development

    MaxCyte signs platform licence with Moonlight Bio to advance T cell therapies for solid tumours

    MaxCyte has entered a strategic platform licence with US biotech [...]

    October 13, 2025
  • European biotech,Events and Conferences,Global health,Healthcare leadership,Market Access & Commercialization,Partnerships & Funding,Research & Development

    Nordic Life Science Days 2025 opens in Gothenburg with calls for deeper collaboration and global investment

    The Nordic Life Science Days 2025 opened today (October 13) [...]

    October 13, 2025
  • Genomics and sequencing,Research & Development

    SPT Labtech and Agilent launch automated target enrichment workflows for genomic sequencing

    SPT Labtech and Agilent Technologies have introduced automated target enrichment [...]

    January 26, 2026
  • Biologics & Biosimilars,Biotech,Drug Development,Research & Development,Technology and platforms

    Confo Therapeutics secures VLAIO grant to develop ultra-long-acting GPCR antibody therapies

    Confo Therapeutics has been awarded a EUR 1 million grant [...]

    October 8, 2025
  • Cell & Gene Therapy,Clinical Development,Research & Development,Technology and platforms

    Circio unveils data showing 40-fold increase in AAV gene delivery efficiency with circVec technology

    Circio Holding has presented new in vivo data showing its [...]

    October 8, 2025
  • Chronic diseases,Market Access & Commercialization,Pharmaceuticals and therapeutics,Research & Development

    Atrial fibrillation market forecast to decline to $10.5bn by 2032 amid NOAC sales erosion

    The atrial fibrillation (AF) market across the eight major markets [...]

    October 7, 2025
  • Clinical Development,Clinical Trials,Obesity,Pharmaceuticals and therapeutics,Research & Development

    Skye Bioscience Phase 2a data show added weight loss with nimacimab–semaglutide combination

    Skye Bioscience has reported topline results from its Phase 2a [...]

    October 7, 2025
  • Biotech,Genomics and sequencing,Partnerships & Funding,Rare Diseases,Research & Development

    Chiesi and Arbor partner on rare disease gene editing programmes targeting PH1 and other liver disorders

    Chiesi Group has entered into an exclusive global partnership with [...]

    October 7, 2025
  • Clinical Development,Clinical studies,Clinical Trials,Oncology,Partnerships & Funding,Pharmaceuticals and therapeutics,Research & Development

    CytoAgents receives fourth NIH grant to advance research on cytokine release syndrome in CAR T-cell therapy

    CytoAgents, a clinical-stage biotechnology company developing an oral small-molecule immune [...]

    October 7, 2025
Previous151617Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • PRISM ALS initiative develops patient-derived stem cell models to improve ALS/MND drug discovery
    Categories: Clinical Development, Clinical Trials, Rare Diseases, Research & Development, Technology and platforms
  • Proxygen appoints Chiara Conti as chief scientific officer to support move into clinical-stage development
    Categories: Biotech, Drug discovery, Healthcare leadership, Movers & Shakers, Research & Development, Startups and innovations, Technology and platforms
  • Efzimfotase alfa shows mixed Phase 3 results in hypophosphatasia across pediatric and adult patients
    Categories: Clinical Development, Clinical Trials, Rare Diseases, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top